DAY 301
Alternative Names: CB-002 - Day One Biopharmaceuticals; DAY-301; MTX-13Latest Information Update: 17 Jan 2025
At a glance
- Originator MabCare Therapeutics
- Developer Day One Biopharmaceuticals; MabCare Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 18 Nov 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (IV) (NCT06752681)
- 30 Jul 2024 Day One Biopharmaceuticals plans a phase I portion of the phase I/IIa for Solid tumours in the fourth quarter of 2024 or first quarter of 2025
- 18 Jun 2024 Day One Biopharmaceuticals in-licenses DAY-301 from MabCare Therapeutics to develop, manufacture, and commercialize worldwide, excluding Greater China